Torii

Immuno-oncology in 2019: the rapid evolution continues

BMS led the charge when Opdivo became the first in its class to gain approval (in metastatic melanoma in December 2014 in Japan), but Merck &Co’s Keytruda has emerged as

Pfizer closes on EU approval of lung cancer drug Vizimpro

The drug is also under regulatory review for this indication in the US and Japan, and the new use could help AZ compete in the market with SGLT2 rivals Invokana (canagliflozin)

Ashfield partners with MIMS, WA Health wins new account and Lighthouse relocates

Ashfield operates across a further three regions – US, Japan and Europe, but hopes the new alliance will provide further expertise in data-driven market and events management.

IQVIA sees market slowdown looming for pharma

the next few years in the 3% to 6% range, mainly due to sluggish growth in Europe, and static or shrinking sales in Japan. ... On the other hand, in Japan for example it says that growth in new products will be strong and resistant to price cuts, despite

Unlocking the potential of science and technology in the UK

The context here is worth keeping in mind. According to World Bank figures, Korea (4.2%), Japan (3.3%), the United States (2.8%), Germany (2.8%), Switzerland (2.4%), France

[ Previous 5 results ] 5 6 7 8 9 10 11 12 13 14 [ Next 5 results ]